Peritoneal Effluent MicroRNA Profile for detection of Encapsulating Peritoneal Sclerosis.
暂无分享,去创建一个
Hui-Yin Chang | Shih-Hua Lin | Y. Hsu | C. Chou | Chiu-Ching Huang | Nianhan Ma | C. Tseng | I. Wang | Chien-Lung Chen | Chiung-Tong Chen | An-Lun Li | Jin-Bor Chen | Kun-Lin Wu | J. Tsai | Chih-Hsun Wu | Yi-Fan Chan
[1] Yongfei Hu,et al. RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility , 2021, Nucleic Acids Res..
[2] Xiaoli Chen,et al. MiR‐17‐5p downregulation alleviates apoptosis and fibrosis in high glucose‐induced human mesangial cells through inactivation of Wnt/β‐catenin signaling by targeting KIF23 , 2021, Environmental toxicology.
[3] C. Chou,et al. A Matrix Metalloproteinase-2-Based Nomogram to Assess the Risk of Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients , 2021, BioMed research international.
[4] Zhizhan Ni,et al. Sclerosing encapsulating peritonitis as a rare cause of intestinal obstruction after the treatment of peritoneal mesothelioma: a case report and review of the literature , 2021, Translational cancer research.
[5] P. Zhou,et al. MiRNA-155-5p inhibits epithelium-to-mesenchymal transition (EMT) by targeting GSK-3β during radiation-induced pulmonary fibrosis. , 2020, Archives of biochemistry and biophysics.
[6] Cheng Chen,et al. miR-155-5p Implicates in the Pathogenesis of Renal Fibrosis via Targeting SOCS1 and SOCS6 , 2020, Oxidative medicine and cellular longevity.
[7] J. Xia,et al. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology , 2020, Nucleic Acids Res..
[8] L. G. Vu,et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.
[9] Yingying Chen,et al. Inhibition of miR-155-5p Exerts Anti-Fibrotic Effects in Silicotic Mice by Regulating Meprin α , 2019, Molecular therapy. Nucleic acids.
[10] Jorng-Tzong Horng,et al. Plasma miRNA profile is a biomarker associated with urothelial carcinoma in chronic hemodialysis patients. , 2019, American journal of physiology. Renal physiology.
[11] Zhi-Yong Guo,et al. HIF1A and VEGF regulate each other by competing endogenous RNA mechanism and involve in the pathogenesis of peritoneal fibrosis. , 2019, Pathology, research and practice.
[12] Hui-Ying Wu,et al. Overexpression of microRNA-202-3p protects against myocardial ischemia-reperfusion injury through activation of TGF-β1/Smads signaling pathway by targeting TRPM6 , 2019, Cell cycle.
[13] N. Khandelwal,et al. Encapsulating Peritoneal Sclerosis: The Abdominal Cocoon. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.
[14] Shih-Chieh Lin,et al. microRNA expression pattern as an ancillary prognostic signature for radiotherapy , 2018, Journal of Translational Medicine.
[15] I. MacRae,et al. Regulation of microRNA function in animals , 2018, Nature Reviews Molecular Cell Biology.
[16] Martin P. Smith,et al. Encapsulating peritoneal sclerosis , 2010, Radiopaedia.org.
[17] Chiu-Ching Huang,et al. Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS , 2018, PloS one.
[18] Henning Hermjakob,et al. The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..
[19] Q. Qian,et al. The MicroRNA-199a/214 Cluster Targets E-Cadherin and Claudin-2 and Promotes High Glucose-Induced Peritoneal Fibrosis. , 2017, Journal of the American Society of Nephrology : JASN.
[20] David W. Johnson,et al. Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis — Position Paper for ISPD: 2017 Update , 2017, Peritoneal Dialysis International.
[21] Hui Luo,et al. MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[22] David W. Johnson,et al. Changes in the worldwide epidemiology of peritoneal dialysis , 2017, Nature Reviews Nephrology.
[23] B. C. Kwan,et al. Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. , 2017, Clinica chimica acta; international journal of clinical chemistry.
[24] R. Y. Cao,et al. The Emerging Role of MicroRNA-155 in Cardiovascular Diseases , 2016, BioMed research international.
[25] Deguang Yang,et al. Role of Mir-155 in Controlling HIF-1α Level and Promoting Endothelial Cell Maturation , 2016, Scientific Reports.
[26] D. Iliopoulos,et al. Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] F. Schena,et al. Role of miR-422a and kallikrein-related peptidase 4 implicated in the development of lupus nephritis. Do we work in this direction? , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] Bicheng Chen,et al. MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis , 2015, Oncotarget.
[29] A. Garg,et al. Worldwide access to treatment for end-stage kidney disease: a systematic review , 2015, The Lancet.
[30] D. Struijk,et al. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] M. Betjes,et al. Lower Mortality and Inflammation from Post-Transplantation Encapsulating Peritoneal Sclerosis Compared to the Classical Form , 2013, American Journal of Nephrology.
[32] Amit X Garg,et al. Global trends in rates of peritoneal dialysis. , 2012, Journal of the American Society of Nephrology : JASN.
[33] Xu Gao,et al. MiR‐483‐5p controls angiogenesis in vitro and targets serum response factor , 2011, FEBS letters.
[34] R. Krediet,et al. Encapsulating peritoneal sclerosis: the state of affairs , 2011, Nature Reviews Nephrology.
[35] Hester F. Lingsma,et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] Jessica A. Weber,et al. The microRNA spectrum in 12 body fluids. , 2010, Clinical chemistry.
[37] D. Struijk,et al. EARLY DIAGNOSTIC MARKERS FOR ENCAPSULATING PERITONEAL SCLEROSIS: A CASE-CONTROL STUDY , 2010, Peritoneal Dialysis International.
[38] R. Pecoits-Filho,et al. Peritoneal Dialysis in the Developing World: Recommendations from a Symposium at the Ispd Meeting 2008 , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[39] K. Simpson,et al. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[40] M. Wilkie,et al. Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications , 2009, Nephron Clinical Practice.
[41] W. Gedroyc,et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[42] J. Jimenez-Heffernan,et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. , 2007, Journal of the American Society of Nephrology : JASN.
[43] P. Brenchley,et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. , 2005, Kidney international.
[44] Y. Kawaguchi,et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[45] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[46] S. Kuriyama,et al. Corticosteroid therapy in encapsulating peritoneal sclerosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.